mutLBSgeneDB

mutLBSgeneDB
mutated Ligand Binding Site gene DataBase

Home

Download

 Statistics

Help

About Us
Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for LGALS3
Gene summary
Basic gene Info.Gene symbolLGALS3
Gene namelectin, galactoside-binding, soluble, 3
SynonymsCBP35|GAL3|GALBP|GALIG|L31|LGALS2|MAC2
CytomapUCSC genome browser: 14q22.3
Type of geneprotein-coding
RefGenesNM_001177388.1,
NM_002306.3,NR_003225.2,
Description35 kDa lectinIgE-binding proteinMAC-2 antigencarbohydrate-binding protein 35galactose-specific lectin 3galectin-3laminin-binding proteinlectin L-29
Modification date20141222
dbXrefs MIM : 153619
HGNC : HGNC
Ensembl : ENSG00000131981
HPRD : 01090
HPRD : 17026
Vega : OTTHUMG00000171030
ProteinUniProt: P17931
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_LGALS3
BioGPS: 3958
PathwayNCI Pathway Interaction Database: LGALS3
KEGG: LGALS3
REACTOME: LGALS3
Pathway Commons: LGALS3
ContextiHOP: LGALS3
ligand binding site mutation search in PubMed: LGALS3
UCL Cancer Institute: LGALS3
Assigned class in mutLBSgeneDBC: This gene just belongs to mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez
GO IDGO TermPubMed ID
GO:0002548monocyte chemotaxis10925302
GO:0030593neutrophil chemotaxis10925302
GO:0045806negative regulation of endocytosis19706535
GO:0048245eosinophil chemotaxis10925302
GO:0048246macrophage chemotaxis10925302
GO:0050918positive chemotaxis10925302
GO:0070232regulation of T cell apoptotic process8692888
GO:0071674mononuclear cell migration10925302
GO:0071677positive regulation of mononuclear cell migration10925302
GO:0090280positive regulation of calcium ion import10925302
GO:2001237negative regulation of extrinsic apoptotic signaling pathway22761016


Top
Ligand binding site mutations for LGALS3

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
W181W181RSTAD1
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.


Top
Protein structure related information for LGALS3
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
W181W181R-0.41024394
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for LGALS3 from PDB

Top
Differential gene expression and gene-gene network for LGALS3
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of LGALS3 and the right PPI network was created from samples without mutations in the LBS of LGALS3. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Top

Top
Phenotype information for LGALS3
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type
umls:C0025202Melanoma11AlteredExpression, Biomarker
umls:C0023893Liver Cirrhosis, Experimental2Biomarker
umls:C0027697Nephritis2AlteredExpression, Biomarker, Therapeutic
umls:C0038356Stomach Neoplasms2Biomarker
umls:C0014859Esophageal Neoplasms1Biomarker
umls:C0000786Abortion, Spontaneous1Biomarker
umls:C0007621Cell Transformation, Neoplastic1Biomarker
umls:C0860207Drug-Induced Liver Injury1Biomarker
umls:C0027540Necrosis1Biomarker

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Top
Pharmacological information for LGALS3
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.

Gene-centered drug-gene interaction network
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure
ExperimentalDB018272,3,5,6-Tetrafluoro-4-Methoxy-BenzamideSmall molecule

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of LGALS3 go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS
GALBETA-D-GALACTOSE1a3kAW181
GALBETA-D-GALACTOSE1kjlAW181
GALBETA-D-GALACTOSE1kjrAW181
GALBETA-D-GALACTOSE2nmnAW181
GALBETA-D-GALACTOSE2nmoAW181
GOLGLYCEROL2nmoAW181
LATBETA-LACTOSE2nn8AW181
LBTALPHA-LACTOSE2nn8AW181
UNUBENZAMIDE2xg3AW181
GALBETA-D-GALACTOSE2xg3AW181
GALBETA-D-GALACTOSE3ayaAW181
GALBETA-D-GALACTOSE3ayaBW181
GALBETA-D-GALACTOSE3aycBW181
GALBETA-D-GALACTOSE3aydAW181
LATBETA-LACTOSE3ayeAW181
MQTMETHYL 2-O-ACETYL-3-O-(4-METHYLBENZOYL)-BETA-D-TALOPYRANOSIDE3t1lAW181
DQTMETHYL 3-DEOXY-2-O-(4-METHYLBENZOYL)-3-[(4-METHYLBENZOYL)AMINO]-BETA-D-TALOPYRANOSIDE3t1mAW181
LATBETA-LACTOSE3zsjAW181
GOLGLYCEROL3zskAW181
TDGTHIODIGALACTOSIDE4jc1AW181
GALBETA-D-GALACTOSE4lbjAW181
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE4lbkAW181
GALBETA-D-GALACTOSE4lbkAW181
GALBETA-D-GALACTOSE4lblAW181
GALBETA-D-GALACTOSE4lbmAW181
GALBETA-D-GALACTOSE4lbnAW181
GALBETA-D-GALACTOSE4lboAW181
70BBIS-(3-DEOXY-3-(3-METHOXY-BENZAMIDO)-B-D- GALACTOPYRANOSYL)-SULFIDE4bljAW181
A6J(3-DEOXY-3-(2,3,5,6-TETRA-FLUORO-4-METHOXY- BENZAMIDO)-B-D-GALACTOPYRANOSYL)-(3-DEOXY-3-(2, 3,5,6-TETRA-FLUORO-4-METHOXY-BENZAMIDO)-2-O- SULFO-B-D-GALACTOPYRANOSYL)-SULFIDE4bm8AW181
LATBETA-LACTOSE4r9aAW181
LATBETA-LACTOSE4r9bAW181
LATBETA-LACTOSE4r9cAW181
LATBETA-LACTOSE4r9dAW181
LATBETA-LACTOSE4rl7AW181
GALBETA-D-GALACTOSE4xbnAW181


Top
Conservation information for LBS of LGALS3
Multiple alignments for P17931 in multiple species
LBSAA sequence# speciesSpecies


Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas